The present invention generally relates to systems and methods for removing acute blockages from blood vessels during intravascular medical treatments.
Clot retrieval catheters and devices are used in mechanical thrombectomy for endovascular intervention, often in cases where patients are suffering from conditions such as acute ischemic stroke (AIS), myocardial infarction (MI), and pulmonary embolism (PE). The immediate hours after these life-threatening events are critical, as a clot that occurs within a blood vessel must be removed as soon as possible to prevent long term disability, brain damage, or death. Accessing the neurovascular bed can be challenging with conventional technology, as the target vessels are small in diameter, remote relative to the site of insertion, and highly tortuous. Traditional devices are often either too large in profile, lack the deliverability and flexibility needed to navigate tortuous vessels, or are not entirely effective at removing a clot when delivered to the target site. Further, tissue plasminogen activator (“tPA”) has been the traditional, FDA-approved treatment for removing blood clots in the brain; however, when the blood clot is in a major blood vessel, tPA can become less effective. This drawback has stimulated the need for a device that can effectively and quickly remove blood clots in major blood vessels.
The clot itself can additionally complicate procedures by embodying a number of complex morphologies and consistencies, ranging from simple tube-shaped structures which assume the shape of the vessel to long, strand-like arrangements that can span multiple vessels at one time. The age of a clot can also affect its compliance, with older clots tending to be less compressible than fresh clots. Experience has also demonstrated that depending on the nature of the interaction with a clot retrieval device, the mechanical properties of a clot can be affected in a significant way. Additionally, several mechanisms can play a role in strongly adhering the clot to the vessel wall. Breaking these bonds without damaging fragile neurovascular vessels can be a significant challenge.
The delivery of effective devices to the small and highly-branched cerebral artery system remains challenging, and conventional clot retrieval devices can suffer from a number of drawbacks. The retrieval device must also be sufficiently flexible to navigate the vasculature and endure high strains, while also having the axial stiffness to offer smooth advancement along the route. Once at the target site, typical objects to be retrieved from the body are substantially larger in size than the device, making it more difficult to retrieve objects into the tip. For example, firm, fibrin-rich clots can often be difficult to extract as they can become lodged in the tip of traditional fixed-mouth catheters and devices. Additionally, this lodging can cause softer portions to shear away from the firmer regions of the clot.
Small diameters and fixed tip sizes are also less efficient at directing the aspiration necessary to remove blood and thrombus material during the procedure. The suction must be strong enough such that any fragmentation that can occur as a result of aspiration or the use of a mechanical thrombectomy device can be held stationary so that fragments cannot migrate and occlude distal vessels. However, when aspirating with a fixed-mouth catheter or device, a significant portion of the aspiration flow ends up coming from vessel fluid proximal to the tip of the catheter or device, where there is no clot. This can significantly reduce aspiration efficiency, lowering the success rate of clot removal.
Applicants therefore recognize a need for improved methods, devices, and systems that can incorporate an expansile funnel that deploys outside a catheter, allowing for effective and quick retrieval of blood clots due to the greater thrombus removal force resulting from the increased area engaging the thrombus. Additionally, there is a need for improved methods, devices, and systems that incorporate a stent retriever having an expandable framework that functions as a funnel catheter tip extension to provide effective and quick retrieval of blood clots.
Generally, system for retrieving a blood clot in a blood vessel using a clot retrieval device having an expansile funnel that can engage with the blood clot is provided. The present disclosure also includes a clot retrieval device having an expandable framework that can engage with the blood clot. The expansile funnel and expandable framework can expand from a collapsed delivery state to an expanded deployed state, increasing the cross-sectional area of the clot retrieval device engaging the blood clot. The increased cross-sectional area of the clot retrieval device can increase the aspiration suction force, providing effective removal of the clot from the patient.
An example system for retrieving an obstruction in a blood vessel can include an outer catheter facilitating the introduction of microcatheters, guidewires, or any of a number of commercially available products to a target site within the vasculature. The outer catheter can be one or both of a guide catheter and an intermediate catheter. Within the outer catheter can be a clot retrieval device. The clot retrieval device can include an elongate flexible delivery wire having a distal end; an expansile tube having a lumen and being affixed to the distal end of the elongated flexible wire; and an expansile funnel affixed to the expansile tube. The expansile funnel can be expandable from a collapsed delivery state, in which the expansile funnel can have a circumference approximately the size of the lumen of the outer catheter, to an expanded deployed state, in which the expansile funnel can have a circumference greater than the circumference of the lumen of the outer catheter. The expansile funnel can include a fluid-impermeable flexible tube; an open distal mouth at the distal end of the flexible tube; and a first and second ring of struts affixed to and structurally supported by the flexible tube. The fluid-impermeable flexible tube can include a lumen in fluid communication with the lumen of the expansile funnel. The second ring of struts can be positioned proximal to the first ring of struts. An aspiration source can be attached to the system to apply suction through a fluidic passage of the outer catheter and the clot retrieval device.
When the expansile funnel is in the expanded deployed state, approximately half of the clot retrieval device can be positioned within the lumen of the outer catheter, while approximately half of the clot retrieval device can be positioned within a blood vessel.
When the expansile funnel is in the expanded deployed state and the expansile tube is positioned within the lumen of the outer catheter, the outer walls of the expansile tube can form a seal against the lumen of the outer catheter.
When the expansile funnel is in the expanded deployed state, the expansile funnel can expand to circumferentially appose a lumen of the blood vessel.
When the expansile funnel is in the collapsed delivery state, a portion of the expansile funnel and the expansile tube can have common circumferential dimensions.
When the expansile funnel is in the collapsed delivery state and is positioned within the lumen of the outer catheter, the lumen of the flexible tube, the lumen of the expansile tube, and the lumen of the outer catheter can be aligned coaxially about a longitudinal axis.
The fluid-impermeable flexible tube can provide the sole structural support for the expansile funnel between the first and second ring of struts. The fluid-impermeable flexible tube can be stitched and/or adhered to the first ring of struts and the second ring of struts. The fluid-impermeable flexible tube can include flexible polymer material.
Another example system can include an outer catheter facilitating the introduction of microcatheters, guidewires, or any of a number of commercially available products to a target site within the vasculature. The outer catheter can be one or both of a guide catheter and an intermediate catheter. Within a lumen of the outer catheter can be a stent retriever. The stent retriever can include an elongate flexible delivery wire; an expandable framework; and a fluid-impermeable membrane. The expandable framework can engage and capture the obstruction within a blood vessel by expanding from a collapsed delivery configuration to an expanded deployed configuration. A proximal end of the expandable framework can be attached to a distal end of the delivery wire. The expandable framework can include a tubular portion that can have an elongated tubular shape when expanded. The expandable framework can taper proximally from the tubular portion to the distal end of the delivery wire. The fluid-impermeable membrane can be affixed to the expandable framework near the proximal end of the framework such that the fluid-impermeable membrane has a funnel shape when the expandable framework is in the expanded configuration.
The tubular portion of the expandable framework can have multiple cell openings sized to pass through the obstruction when the expandable framework expands from the collapsed delivery configuration.
The system can include the expandable framework including a closed distal end portion extending distally away from the tubular portion of the framework and radially inward towards a central axis.
The tubular portion can be expandable to have approximately the same circumference as the circumference of the blood vessel when the expandable framework is in the expanded deployed configuration, allowing for complete engagement with the obstruction.
The system can include a microcatheter sized to traverse the lumen of the outer catheter. The expandable framework can be sized to traverse a lumen of the microcatheter when in the collapsed delivery state.
When deployed a blood vessel as part of a treatment, the fluid-impermeable membrane can include a first outer circumference approximately equal to an inner circumference of the lumen of the outer catheter and a second outer circumference approximately equal to the inner circumference of the blood vessel. When the expandable framework is in the expanded configuration, a portion of the proximal portion of the expanded framework can be positioned within the lumen of the outer catheter. This configuration can provide an outer force on the lumen of the outer catheter such that a fluid-impermeable seal is created between the fluid-impermeable membrane and the lumen of the outer catheter. This configuration can further provide a force between the fluid impermeable membrane and the walls of the blood vessel such that a fluid-impermeable seal is created between the fluid-impermeable membrane and the walls of the blood vessel.
An example method for retrieving an obstruction from a blood vessel can include one or more of the following steps presented in no particular order. The example method can include additional steps as would be appreciated and understood by a person of ordinary skill in the art. The example method can be performed by an example system as disclosed herein, a variation thereof, or an alternative thereto as would be appreciated and understood by a person of ordinary skill in the art.
The method can include accessing an arterial blood vessel of a patient using an outer catheter; positioning a distal end of the outer catheter proximate to the obstruction; advancing a microcatheter and an expandable framework having a fluid-impermeable membrane, in a collapsed delivery state, through the lumen of the outer catheter; crossing the obstruction with the microcatheter and the expandable framework in the collapsed configuration; retracting the microcatheter into the lumen of the outer catheter while the expandable framework maintains contact with the obstruction; expanding a portion of the expandable framework through the obstruction; expanding a distal portion and proximal portion of the membrane to circumferentially appose the lumen of the outer catheter; and aspirating through a fluidic passage.
The method can include advancing the outer catheter to a distance approximately three millimeters away from the obstruction.
The method can include retracting a portion of the expandable framework into the lumen of the outer catheter while aspirating resulting in removing the expandable framework with the obstruction from the patient.
The method can include injecting contrast media within the lumen of the outer catheter to assess the degree of obstruction remaining in the blood vessel.
The above and further aspects of this invention are further discussed with reference to the following description in conjunction with the accompanying drawings, in which like numerals indicate like structural elements and features in various figures. The drawings are not necessarily to scale, emphasis instead being placed upon illustrating principles of the invention. The figures depict one or more implementations of the inventive devices, by way of example only, not by way of limitation. It is expected that those of skill in the art can conceive of and combining elements from multiple figures to better suit the needs of the user.
Specific examples of the present invention are now described in detail with reference to the Figures, where identical reference numbers indicate elements which are functionally similar or identical.
A key success factor in intravascular treatment such as aneurysm treatments relates to the obstruction removal force defined as the product of the vacuum pressure times the catheter cross sectional area. In some treatments, mechanical clot removal devices referred to herein generically as “stent retrievers” are also used in combination with aspiration. In order to increase the obstruction removal force, either the vacuum pressure or the catheter cross-sectional area can be increased. The disclosed technology relates to a clot retrieval device including an expansile funnel that can increase the cross-sectional area of the device that can be in contact with the obstruction. Alternatively, the disclosed technology relates to a stent retriever including an expandable framework having a membrane thereon that can provide a sealed opening to the catheter lumen, the sealed opening providing a cross sectional area in contact with the obstruction that is greater than the catheter cross sectional area. Because the cross-sectional area is increased, the obstruction removal force can be increased, resulting in improved removal of an obstruction from a patient compared to suction through the catheter alone.
Accessing the various vessels within the vascular, whether they are coronary, pulmonary, or cerebral, involves well-known procedural steps and the use of a number of conventional, commercially-available accessory products. These products, such as angiographic materials, rotating hemostasis valves, and guidewires are widely used in laboratory and medical procedures. When these products are employed in conjunction with the system and methods of this invention in the description below, their function and exact constitution are not described in detail.
Referring collectively to
The clot retrieval device 100, 100a, 100b can include a flexible delivery member 102 (also referred to herein generically as “delivery wire”), an expansile tube 104, and an expansile funnel 106. The expansile tube 104 can be affixed at a distal end of the delivery wire 102, and the expansile funnel 106 can extend distally from the expansile tube 104. The clot retrieval device 100 including the delivery wire 102, expansile tube 104, and expansile funnel 106 can be sized to fit within the lumen 202 of the outer catheter 200. The device 100, 100a, 100b can, but need not include a defined transition between the expansile tube 104 and the expansile funnel 106.
During delivery of the system 10, 10a, 10b through vasculature, the device 100, 100a, 100b can be retained completely within the lumen 202 of the outer catheter 200 as the catheter 200 is translated through vasculature. Once the distal end of the catheter 200 is positioned near the obstruction (T), the delivery wire 102 can be pushed distally to move the expansile funnel 106 distally out of the lumen 202 of the catheter 200. The expansile funnel 106 can be expandable to circumferentially appose the walls of the blood vessel on the proximal side of the obstruction (T) while the expansile tube 104 remains positioned within the lumen 202 of the catheter 200. The distal mouth 108 of the expansile funnel 106 can have a circumference 210 when expanded in the blood vessel (BV) that is approximately equal to the circumference 212 of the interior of the blood vessel (BV). The expansile funnel 106 can therefore be expandable to an expanded deployed state having an outer circumference 210 that is greater than the circumference 208 of the lumen 202 of the outer catheter 200. The expansile funnel 106 can provide fluidic passage to a lumen 105 of the expansile tube 104. The lumen 105 of the expansile tube 104 can be in fluidic communication with the lumen 202 of the catheter 200 such that when the aspiration source (AS) is applied, the aspiration force can sufficiently reach the obstruction (T). The expansile tube 104 can expand to have an outer circumference that is approximately equal to the circumference 208 of the lumen 202 of the outer catheter 200.
The expansile tube 104 can be disposed proximate to the distal end of the delivery wire 102. The expansile tube 104 can be affixed to a plurality of connecting struts 120 disposed on the distal end of the delivery wire 102. The expansile tube 104 can expand and retract to accommodate delivery catheters having different diameters.
Referring collectively to
The expansile funnel 106 can be affixed to the distal end of the expansile tube 104. The expansile funnel 106 can be expanded from a collapsed delivery state to an expanded deployed state. In the collapsed delivery state, the expansile funnel 106 is sized to traverse the lumen 202 of the outer catheter 200. In this configuration, the expansile funnel 106 can be folded or collapsed upon itself in order to adequately fit within the lumen 202 of the outer catheter 200. The expansile funnel 106 can fold or collapse radially inward towards a longitudinal axis. In the collapsed delivery state, at least a portion of the expansile funnel 106 and the expansile tube 104 can have a common circumference. In the collapsed delivery state, the lumen 111 of a fluid-impermeable flexible tube 110, the lumen 105 of the expansile tube 104, and the lumen 202 of the outer catheter 200 can be aligned coaxially about a longitudinal axis (LA). In this configuration, the clot retrieval device 100 can be transported through the body using catheters of varying diameters until the clot retrieval device 100 is proximate to the obstruction (T) in the blood vessel (BV).
The expansile funnel 106 can assume the expanded configuration by self-extending radially outward from the longitudinal axis upon exiting the distal end of the outer catheter 200. In one example in which the expansile funnel 106 can be folded or compressed, when the expansile funnel 106 is in the collapsed delivery state, the expansile funnel 106 can provide a spring-like force that facilitates self-expansion of the expansile funnel 106 when the expansile funnel 106 exits the outer catheter 200. In the expanded deployed state, the expansile funnel 106 can expand such that the expansile funnel 106 has an outer circumference 210 greater than the circumference 208 of the lumen 202 of the outer catheter 200. In one example, the expansile funnel 106, when in the expanded deployed state, can have a circumference 210 approximately equal to the circumference 212 of the interior of the blood vessel (BV). The expansile funnel 106 can thus seal with the blood vessel (BV) or create enough of a restriction such that when aspiration is applied, blood and the clot distal of the distal mouth 108 of the expansile funnel 106 will be drawn into the clot retrieval device 100, 100a, 100b rather than blood proximal of the expansile funnel 106. In the expanded deployed state, at least a portion of the clot retrieval device 100 can be positioned within the lumen 202 of the outer catheter 200. In one example, in the expanded deployed state, approximately half of the clot retrieval device 100, 100a, 100b can be positioned within the lumen 202 of the outer catheter 200. The clot retrieval device 100, 100a, 100b can be positioned coaxially along a longitudinal axis (LA) within the lumen 202 of the outer catheter 202. In the expanded deployed state, at least a portion of the clot retrieval device 100, 100a, 100b can be positioned within the lumen of the blood vessel (BV). In one example, in the expanded deployed state, approximately half of the clot retrieval device 100, 100a, 100b can be positioned within the lumen of the blood vessel (BV).
The expansile funnel 106 can include a distal mouth 108. In the expanded deployed state, the distal mouth 108 can be open and configured to engage the obstruction (T). The open distal mouth 108 can have a circumference approximately equal to the circumference 212 of the blood vessel (BV). The distal mouth 108 can have a circumference approximately equal to or larger than the circumference of the obstruction (T). Because the open distal mouth 108 has a circumference approximately equal to or larger than the circumference of the obstruction, the distal mouth 108 of the expansile funnel 106 can engage and receive the obstruction (T). When the aspiration source is connected and suction begins, the obstruction expansile funnel 106 can further receive the obstruction (T), such that the obstruction (T) can be pulled into the expansile funnel 106, and particularly into the lumen 111 of the fluid-impermeable flexible tube 110. The expansile funnel 106 can be progressively compressed during retrieval of the obstruction (T) to a small diameter so that it can be fully received within the expansile tube 104 of the clot retrieval device 100, 100a, 100b. The obstruction (T) can then be safely and effectively removed from the patient. If the obstruction (T) does become lodged in the distal mouth 108, the open mouth 108 will protect the obstruction (T) and prevent it from dislodging as the aspiration suction is maintained and the clot retrieval device 100, 100a, 100b is retracted into the sheath or outer catheter 200.
The large distal mouth 108 of the clot retrieval device 100, 100a, 100b of systems 10, 10a, 10b illustrated herein can offer improved performance over conventional fixed-mouth designs. Traditional fixed-mouth catheters can be hindered by having firm, fibrin-rich clots lodge in the tip of a catheter, or by having softer portions of the clot shear away. When aspirating through a fixed-mouth catheter, a significant portion of the suction can be directed to fluid proximal of the tip, reducing the suction directed to the clot and the success rate of clot removal. As the diameter of an expandable distal mouth 108 can be close to that of the vessel, clot shearing at the mouth of the catheter can be mitigated and the volume of fluid and clot distal of the mouth secured. However, the expansile funnel 106 of the disclosed technology can increase the amount of suction force by increasing the cross-sectional area of engagement between the expansile funnel and the obstruction, resulting in more effective removal of an obstruction (T).
The clot capture devices 100a, 100b illustrated in
Likewise, the cover 110b (fluid-impermeable flexible tube, membrane, coating, or other cover) of the device 100b illustrated in
Referring collectively to
The strut framework 116a, 116b can have a variety of configurations that are not illustrated in
In one example, the cover 110, 110a, 110b can include a fluid-impermeable flexible tube that provides the sole structural support of the expansile funnel 106. As illustrated in
The ideal diameter of the clot retrieval device 100, 100a, 100b depends on the location of the target obstruction and the diameter of the outer catheter 200 through which the clot retrieval device 100, 100a, 100b can be delivered. For retrieval of clots in the cerebral vascular bed, where vessel diameters commonly around 3 mm to 6 mm, an applicable system might have an outer catheter 200 with an inner diameter of about 0.070 inches (1.8 mm) and a clot retrieval device 100 with an inner diameter of about 0.062 inches (1.6 mm). Upon deployment from the outer catheter 200, the maximum diameter of the expansile funnel 106 could be a minimum of 3 mm (but in some instances about 5-6 mm), allowing it to seal against the walls of the blood vessel (BV) and providing an opening at the distal mouth as large as the blood vessel (BV) itself.
Referring collectively to
The funneled stent retriever 300 can include an elongate flexible member 102, referred to herein generically as “a delivery wire”. The delivery wire 102 can facilitate positioning the stent retriever 300 proximate to the obstruction (T). The delivery wire 102 can be coated with hydrophilic and/or hydrophobic lubricious polymer including polyvinylpyrrolidone, polytetrafluoroethylene, or silicone to reduce friction between the components of the system 10c and the components of the system 10c and the blood vessel (BV). The delivery wire 102 can have sufficient flexibility for a physician to maneuver the stent retriever 300 through the blood vessel (BV), but also sufficient stiffness to effectively guide the stent retriever 300 to the target site. In one example, the delivery wire 102 can be solid steel. In another example, the delivery wire 102 can be a Nitinol core wire. In one example, a distal end 103 of the delivery wire 102 can include a plurality of connecting struts 120. The connecting struts 120 can include the same material as the delivery wire 102. The connecting struts 120 can connect the distal end 103 of the delivery wire 102 to the expansile tube 104, as illustrated in
The stent retriever 300 can include an expandable framework 304 configured to engage and capture the obstruction (T). The framework 304 is illustrated having a structure similar to as disclosed in U.S. Pat. No. 9,445,829 which is hereby incorporated by reference as if set forth in its entirety herein. Alternatively, the expanded framework 304 can have a structure similar to other known frameworks of stent retriever devices or variations thereof as understood by a person of ordinary skill in the art according to the teachings of the present disclosure. As a non-exhaustive list of such frameworks of stent retriever devices, U.S. Pat. Nos. 10,292,723, 8,852,205, 9,301,769, 10,229,881, 10,420,570, 10,201,360, and 10,363,054 and U.S. Pat. Pub. Nos. 2017/0071614 are hereby incorporated by reference as if set forth in their entirety herein.
The expandable framework 304 can be made of material capable of self-expanding to an expanded configuration once released from the collapsed delivery state, such as a shape memory material. Additionally, or alternatively, the expandable framework 304 can be made of super elastic material. In one example, the superlattice alloy can be Nitinol or an alloy of similar properties. In one example, the super elastic alloy can include nickel and titanium. The expandable framework 304 can have a plurality of forms. The expandable framework 304 can be manufactured by laser cutting a Nitinol tube and then applying heat and electropolish to create a desired framework. The expandable framework 304 can include a radiopaque marker that can allow the expandable framework 304 to be visible using fluoroscopy.
When the expandable framework 304 is in an expanded deployed configuration, the expandable framework 304 can have a substantially tubular shape. In the expanded deployed configuration, the expandable framework 304 can include a tubular portion 310, a proximal portion 306 and a distal portion 312. The tubular portion 310 can extend distally from the proximal portion 306. The proximal portion 306 of the expandable framework 304 can be fixed to the distal end 103 of the delivery wire 102. In one example, the proximal portion 306 can be fixed to the distal end 103 of the delivery wire 102 by a collar joint 316, as illustrated in
In an alternate example, the proximal portion 306 can be welded to the distal end 103 of the delivery wire 102. When the expandable framework 304 is in an expanded deployed configuration, the proximal portion 306 of the expandable framework 304 can be tapered, such that the proximal portion 306 narrows from the tubular portion 310 to the point at which the expandable framework 304 can be fixed to the delivery wire 102. The tapering of the proximal portion 306 can create a funnel-like shape, as illustrated in
The tapering of the distal portion 312 can create a conical or funnel-like shape, as illustrated in
The ideal diameter of the expandable framework can depend on the location of the target obstruction and the diameter of the outer catheter through which the expandable framework 304 is delivered. For retrieval of clots in the internal carotid artery, where vessel diameters can be between approximately 3 mm and 6 mm, an applicable system 10c can include an expandable framework 304 of between approximately 3 mm and 6 mm. In one example, the expandable framework 304 can be slightly greater than the diameter of the blood vessel (BV), forming a seal with the inner walls of the blood vessel. The ideal length of the expandable framework 304 can depend on the location of the target and characteristics of the obstruction (T). In one example, the length of the expandable framework 304 can be approximately 30 mm. In another example, the length of the expandable framework can be approximately 40 mm.
As illustrated in
The stent retriever 300 can include a fluid-impermeable membrane 308. The fluid-impermeable membrane 308 can be affixed to the proximal portion 306 of the expandable framework 304. The fluid-impermeable membrane 308 can also be affixed to the expandable framework 304 extending into the lumen 202 of the outer catheter 200. The fluid-impermeable membrane 308 can be made of porous material. The porous material can include pores sized to be smaller than the size of blood molecules, thereby preventing blood molecules from passing through the fluid-impermeable membrane 208. The flexible nature of the fluid-impermeable membrane 308 allows the fluid-impermeable membrane 308 to stretch as the expandable framework expands from the collapsed delivery state to the expanded deployed state. As the fluid-impermeable membrane 308 stretches, the membrane 308 can follow the contours of an underlying expandable framework 304. In one example, the fluid-impermeable membrane 308 can cover at least a portion of the proximal portion 306 of the expandable framework 304. In another example, the fluid-impermeable membrane 308 can cover the entire proximal portion 306 of the expandable framework. The fluid-impermeable membrane 308 can cover the proximal portion 306 of the expandable framework 304 extending into the lumen 202 of the outer catheter 200. When the fluid-impermeable membrane 308 covers at least a portion of the proximal portion 306 of the expandable framework 304 and the expandable framework 304 extending into the lumen 202 of the outer catheter 200, a funnel-like shape can be created. The fluid-impermeable membrane 308 can include a proximal opening sized to permit aspiration. In the expanded deployed configuration, the circumference of the proximal opening can be approximately equal to the circumference 208 of the lumen 202 of the outer catheter 200. When an aspiration force is applied, the proximal opening can permit aspiration through the funnel-like shape of the fluid-impermeable membrane, facilitating retrieval of the obstruction (T).
The expandable framework 304 can have a collapsed delivery configuration and an expanded deployed configuration. In the collapsed delivery configuration, system 10c can include a microcatheter 204. The microcatheter 204 can be sized to traverse the lumen 202 of the outer catheter 200. In the collapsed delivery configuration, the expandable framework 304 can collapse into itself such that the expandable framework 304 can be positioned within the lumen 205 of the microcatheter 204.
In the collapsed delivery state, the first outer circumference 212 and the second outer circumference 214 of the fluid-impermeable membrane 308 can be approximately equal. The first circumference 212 and the second circumference 214 can be approximately equal to the circumference 220 of the lumen 205 of the microcatheter 204. In the collapsed delivery state, the first circumference 212, the second outer circumference 214, the circumference 330 of the tubular portion 310 of the expandable framework 304, and the circumference 220 of the lumen 205 of the microcatheter 204 can be approximately equal.
In the expanded deployed state, the tubular portion 310 of the expandable framework 304 can expand such that the circumference 330 of the tubular portion 310 is substantially equal to the circumference 212 of the blood vessel (BV). In one example, the funneled stent retriever 300 can be configured to treat an obstruction (T) having a circumference that is substantially equal to the circumference of the blood vessel (BV). In another example, the funneled stent retriever 300 can be configured to treat an obstruction (T) having a circumference smaller than the circumference of the blood vessel (BV). Because the tubular portion 310 can expand such that its circumference can be substantially equal to the circumference of the blood vessel (BV), the expandable framework 304 can fully engage with the obstruction (T).
In the expanded deployed state, the fluid-impermeable membrane can include a first outer circumference 212 and a second outer circumference 214. The first outer circumference 212 can be approximately equal to the circumference 208 of the lumen 202 of the outer catheter 200, as illustrated in
In the expanded deployed state, the portion of the proximal portion 306 of the expandable framework 304 extending into the lumen 202 of the outer catheter 200 can create an outward force on the inner walls of the outer catheter 200. The outward force can be sufficient to create a fluid-impermeable seal 332 between the fluid-impermeable membrane 308 covering the proximal portion of the expandable framework 304 extending into the lumen 202 of the outer catheter 200 and lumen 202 of the outer catheter 200, as illustrated in
Optimal retrieval of an obstruction (T) from a blood vessel (BV) can depend on obstruction removal force. Obstruction removal force can be defined as the product of vacuum pressure applied multiplied by the cross-section area of the clot retrieval device engaging the obstruction (T). When the thrombus removal force is high, the obstruction (T) can be firmly held to the clot retrieval device, resulting in effective removal of the obstruction (T). Increasing the vacuum pressure applied can be one method of increasing the obstruction removal force. However, vacuum pressure can only be increased to a realistic limit (e.g. based on design constraints as understood by a person of ordinary skill in the art). Further, increasing the internal diameter, and thus, cross-section area of a catheter can present challenges, as larger catheters can be more difficult to track and can increase the potential for vessel damage.
Accordingly, clot retrieval devices 100a, 100b, and 300 as disclosed herein are configured to significantly increase the cross-section area engaging the obstruction (T), and thus increase the obstruction removal force as compared to commercially available products. By way of example, as illustrated in
An artery of the brain can be accessed using a long guide wire 216. Once a distal tip of the guide wire 216 reaches the target site, the guide wire 216 can act as a guide that larger catheters can follow for delivery to the target site. The guide wire 216 can be constructed from solid steel, nitinol core, or other suitable material. In one example, vasculature can be accessed using a guide catheter such as a balloon catheter.
In step 402, an arterial blood vessel of a patient can be accessed using a first catheter 206 comprising a lumen 207, an aspiration catheter 200 comprising a lumen 202, and a microcatheter 204 comprising a lumen 205. As illustrated in
In step 404, the aspiration catheter 200 can be advanced through the lumen 207 of the first catheter 206 and towards a proximal end of the obstruction (T) using conventionally known techniques, as illustrated in
In step 406, a microcatheter 204 having an expandable framework 304 collapsed therein can be advanced through the lumen 202 of the outer catheter 200 and towards the proximal end of the obstruction (T) as illustrated in
In step 408, the microcatheter 204 having the expandable framework 304 collapsed within the lumen 207 of the microcatheter 204 can cross the obstruction (T), as illustrated in
In step 410, the microcatheter 204 can be retracted into the lumen 202 of the outer catheter 200, while a majority of the expandable framework 304 remains across the obstruction (T), as illustrated in
In step 412, at least a portion of the expandable framework 304 can be expanded to engage the obstruction (T), as illustrated in
In step 414, a distal portion of the fluid-impermeable membrane 308 can be expanded, as illustrated in
In step 416, a proximal portion of fluid-impermeable membrane 308 can be expanded, as illustrated in
In step 418, an aspiration source can be connected to the system 10c. The aspiration source can generate a vacuum pressure that can aspirate through a fluidic passage defined by the fluid-impermeable membrane 308 and the lumen 202 of the aspiration catheter 200. The suction can be sufficient to engage the stent retriever 300 and the obstruction (T) during removal of the obstruction.
In step 420, at least a portion of the expandable framework 304 can be retracted into the lumen 202 of the outer catheter 200, as illustrated in
In step 422, the stent retriever 300 can be removed with the captured obstruction (T) from the patient as illustrated in
In one example, the contrast media can be injected within the lumen 202 of the outer catheter 200 to access the degree of obstruction remaining in the blood vessel (BV). The contrast media can include an iodine-based contrast material
The invention is not limited to the examples described, which can be varied in construction and detail. The terms “distal” and “proximal” are used throughout the preceding description and are meant to refer to a positions and directions relative to a treating physician. As such, “distal” or distally” refer to a position distant to or a direction away from the physician. Similarly, “proximal” or “proximally” refer to a position near to or a direction towards the physician.
In describing example embodiments, terminology is resorted to for the sake of clarity. It is intended that each term contemplates its broadest meaning as understood by those skilled in the art and includes all technical equivalents that operate in a similar manner to accomplish a similar purpose. It is also to be understood that the mention of one or more steps of a method does not preclude the presence of additional method steps or intervening method steps between those steps expressly identified. Steps of a method can be performed in a different order than those described herein without departing from the scope of the disclosed technology. Similarly, it is also to be understood that the mention of one or more components in a device or system does not preclude the presence of additional components or intervening components between those components expressly identified.
As discussed herein, a “patient” or “subject” can be a human or any animal. It should be appreciated that an animal can be a variety of any applicable type, including, but not limited to, mammal, veterinarian animal, livestock animal or pet-type animal, etc. As an example, the animal can be a laboratory animal specifically selected to have certain characteristics similar to a human (e.g., rat, dog, pig, monkey, or the like).
As used herein, the terms “about” or “approximately” for any numerical values or ranges indicate a suitable dimensional tolerance that allows the part or collection of components to function for its intended purpose as described herein. More specifically, “about” or “approximately” may refer to the range of values ±20% of the recited value, e.g. “about 90%” may refer to the range of values from 71% to 99%.
By “comprising” or “containing” or “including” is meant that at least the named compound, element, particle, or method step is present in the composition or article or method, but does not exclude the presence of other compounds, materials, particles, method steps, even if the other such compounds, material, particles, method steps have the same function as what is named.
It must also be noted that, as used in the specification and the appended claims, the singular forms “a,” “an,” and “the” include plural referents unless the context clearly dictates otherwise. Ranges can be expressed herein as from “about” or “approximately” one particular value and/or to “about” or “approximately” another particular value. When such a range is expressed, other exemplary embodiments include from the one particular value and/or to the other particular value.
The descriptions contained herein are examples of embodiments of the invention and are not intended in any way to limit the scope of the invention. While particular examples of the present invention are described, various modifications to devices and methods can be made without departing from the scope and spirit of the invention. For example, while the examples described herein refer to particular components, the invention includes other examples utilizing various combinations of components to achieve a described functionality, utilizing alternative materials to achieve a described functionality, combining components from the various examples, combining components from the various example with known components, etc. The invention contemplates substitutions of component parts illustrated herein with other well-known and commercially-available products. Modifications recognized by one having ordinary skill in the art to which this invention relates are intended to be within the scope of the claims which follow.
Number | Name | Date | Kind |
---|---|---|---|
4243040 | Beecher | Jan 1981 | A |
4324262 | Hall | Apr 1982 | A |
4351342 | Wiita et al. | Sep 1982 | A |
4575371 | Nordqvist et al. | Mar 1986 | A |
4592356 | Gutierrez | Jun 1986 | A |
4719924 | Crittenden et al. | Jan 1988 | A |
4738666 | Fuqua | Apr 1988 | A |
4767404 | Renton | Aug 1988 | A |
4793348 | Palmaz | Dec 1988 | A |
4873978 | Ginsburg | Oct 1989 | A |
5011488 | Ginsburg | Apr 1991 | A |
5092839 | Kipperman | Mar 1992 | A |
5102415 | Guenther et al. | Apr 1992 | A |
5122136 | Guglielmi et al. | Jun 1992 | A |
5123840 | Nates | Jun 1992 | A |
5171233 | Amplatz | Dec 1992 | A |
5234437 | Sepetka | Aug 1993 | A |
5256144 | Kraus et al. | Oct 1993 | A |
5261916 | Engelson | Nov 1993 | A |
5372124 | Takayama et al. | Dec 1994 | A |
5385562 | Adams | Jan 1995 | A |
5387219 | Rappe | Feb 1995 | A |
5387226 | Miraki | Feb 1995 | A |
5396902 | Brennen et al. | Mar 1995 | A |
5449372 | Schmaltz | Sep 1995 | A |
5520651 | Sutcu | May 1996 | A |
5538512 | Zenzon et al. | Jul 1996 | A |
5549626 | Miller et al. | Aug 1996 | A |
5558652 | Henke | Sep 1996 | A |
5601600 | Ton | Feb 1997 | A |
5609627 | Goicoechea et al. | Mar 1997 | A |
5624461 | Mariant | Apr 1997 | A |
5639277 | Mariant | Jun 1997 | A |
5645558 | Horton | Jul 1997 | A |
5658296 | Bates | Aug 1997 | A |
5662671 | Barbut | Sep 1997 | A |
5695519 | Summer et al. | Dec 1997 | A |
5709704 | Nott et al. | Jan 1998 | A |
5713853 | Clark | Feb 1998 | A |
5728078 | Powers, Jr. | Mar 1998 | A |
5769871 | Mers Kelly | Jun 1998 | A |
5779716 | Cano | Jul 1998 | A |
5810874 | Lefebvre | Sep 1998 | A |
5814064 | Danniel et al. | Sep 1998 | A |
5827304 | Hart | Oct 1998 | A |
5846251 | Hart | Dec 1998 | A |
5855598 | Pinchuk | Jan 1999 | A |
5893869 | Barnhart et al. | Apr 1999 | A |
5895398 | Wensel | Apr 1999 | A |
5897567 | Ressemann | Apr 1999 | A |
5904698 | Thomas et al. | May 1999 | A |
5911725 | Boury | Jun 1999 | A |
5935139 | Bates | Aug 1999 | A |
5938645 | Gordon | Aug 1999 | A |
5947995 | Samuels | Sep 1999 | A |
5968057 | Taheri | Oct 1999 | A |
5971938 | Hart et al. | Oct 1999 | A |
5997939 | Moechnig et al. | Dec 1999 | A |
6022343 | Johnson et al. | Feb 2000 | A |
6063113 | Kavteladze | May 2000 | A |
6066149 | Samson et al. | May 2000 | A |
6066158 | Engelson | May 2000 | A |
6093196 | Okada | Jul 2000 | A |
6093199 | Brown et al. | Jul 2000 | A |
6096053 | Bates | Aug 2000 | A |
6099534 | Bates | Aug 2000 | A |
6102932 | Kurz | Aug 2000 | A |
6106548 | Roubin et al. | Aug 2000 | A |
6129739 | Khosravi | Oct 2000 | A |
6142957 | Diamond et al. | Nov 2000 | A |
6146396 | Kónya et al. | Nov 2000 | A |
6146404 | Kim | Nov 2000 | A |
6165194 | Denardo | Dec 2000 | A |
6165199 | Barbut | Dec 2000 | A |
6168604 | Cano | Jan 2001 | B1 |
6168622 | Mazzocchi | Jan 2001 | B1 |
6174318 | Bates et al. | Jan 2001 | B1 |
6179861 | Khosravi | Jan 2001 | B1 |
6203561 | Ramee | Mar 2001 | B1 |
6214026 | Epak | Apr 2001 | B1 |
6221006 | Dubrul | Apr 2001 | B1 |
6238412 | Dubrul | May 2001 | B1 |
6245087 | Addis | Jun 2001 | B1 |
6251122 | Tsukernik | Jun 2001 | B1 |
6254571 | Hart | Jul 2001 | B1 |
6264663 | Cano | Jul 2001 | B1 |
6306163 | Fitz | Oct 2001 | B1 |
6309379 | Willard | Oct 2001 | B1 |
6312407 | Zando-Azizi et al. | Nov 2001 | B1 |
6312444 | Barbut | Nov 2001 | B1 |
6315778 | Gambale et al. | Nov 2001 | B1 |
6325819 | Pavcnik et al. | Dec 2001 | B1 |
6334864 | Amplatz et al. | Jan 2002 | B1 |
6336934 | Gilson et al. | Jan 2002 | B1 |
6348056 | Bates | Feb 2002 | B1 |
6350271 | Kurz et al. | Feb 2002 | B1 |
6361545 | Macoviak | Mar 2002 | B1 |
6371963 | Nishtala et al. | Apr 2002 | B1 |
6375668 | Gifford et al. | Apr 2002 | B1 |
6383205 | Samson et al. | May 2002 | B1 |
6383206 | Gillick | May 2002 | B1 |
6391037 | Greenhalgh | May 2002 | B1 |
6402771 | Palmer | Jun 2002 | B1 |
6409683 | Fonseca et al. | Jun 2002 | B1 |
6416541 | Denardo | Jul 2002 | B2 |
6425909 | Dieck et al. | Jul 2002 | B1 |
6432122 | Gilson et al. | Aug 2002 | B1 |
6436112 | Wensel | Aug 2002 | B2 |
6458139 | Palmer | Oct 2002 | B1 |
6346116 | Brooks et al. | Nov 2002 | B1 |
6485497 | Wensel | Nov 2002 | B2 |
6485501 | Green | Nov 2002 | B1 |
6485502 | Don Michael | Nov 2002 | B2 |
6511492 | Rosenbluth | Jan 2003 | B1 |
6517551 | Driskill | Feb 2003 | B1 |
6520934 | Lee et al. | Feb 2003 | B1 |
6520951 | Carrillo, Jr. | Feb 2003 | B1 |
6530935 | Wensel | Mar 2003 | B2 |
6530939 | Hopkins | Mar 2003 | B1 |
6540768 | Diaz et al. | Apr 2003 | B1 |
6544279 | Hopkins | Apr 2003 | B1 |
6551341 | Boylan et al. | Apr 2003 | B2 |
6551342 | Shen et al. | Apr 2003 | B1 |
6575997 | Palmer et al. | Jun 2003 | B1 |
6582448 | Boyle | Jun 2003 | B1 |
6585756 | Strecker | Jul 2003 | B1 |
6589265 | Palmer et al. | Jul 2003 | B1 |
6592607 | Palmer et al. | Jul 2003 | B1 |
6592616 | Stack | Jul 2003 | B1 |
6602271 | Adams | Aug 2003 | B2 |
6602272 | Boylan et al. | Aug 2003 | B2 |
6605102 | Mazzocchi et al. | Aug 2003 | B1 |
6610077 | Hancock et al. | Aug 2003 | B1 |
6616679 | Khosravi | Sep 2003 | B1 |
6632241 | Hanoock et al. | Oct 2003 | B1 |
6638245 | Miller | Oct 2003 | B2 |
6638293 | Makower et al. | Oct 2003 | B1 |
6641590 | Palmer et al. | Nov 2003 | B1 |
6652555 | VanTassel et al. | Nov 2003 | B1 |
6656218 | Denardo et al. | Dec 2003 | B1 |
6660021 | Palmer et al. | Dec 2003 | B1 |
6663650 | Sepetka | Dec 2003 | B2 |
6673089 | Yassour et al. | Jan 2004 | B1 |
6685722 | Rosenbluth | Feb 2004 | B1 |
6692504 | Kurz et al. | Feb 2004 | B2 |
6692508 | Wensel | Feb 2004 | B2 |
6692509 | Wensel | Feb 2004 | B2 |
6702782 | Miller | Mar 2004 | B2 |
6712834 | Yassour et al. | Mar 2004 | B2 |
6726701 | Gilson et al. | Apr 2004 | B2 |
6730104 | Sepetka | May 2004 | B1 |
6726703 | Broome et al. | Aug 2004 | B2 |
6824545 | Sepetka | Nov 2004 | B2 |
6855155 | Denardo et al. | Feb 2005 | B2 |
6878163 | Denardo et al. | Apr 2005 | B2 |
6890340 | Duane | May 2005 | B2 |
6913612 | Palmer | Jul 2005 | B2 |
6913618 | Denardo et al. | Jul 2005 | B2 |
6953472 | Palmer et al. | Oct 2005 | B2 |
6989019 | Mazzocchi | Jan 2006 | B2 |
6989021 | Bosma et al. | Jan 2006 | B2 |
6994718 | Groothuis et al. | Feb 2006 | B2 |
6997939 | Linder | Feb 2006 | B2 |
7004954 | Voss et al. | Feb 2006 | B1 |
7004955 | Shen | Feb 2006 | B2 |
7004956 | Palmer | Feb 2006 | B2 |
7008434 | Kurz et al. | Mar 2006 | B2 |
7033376 | Tsukernik | Apr 2006 | B2 |
7041116 | Goto | May 2006 | B2 |
7048758 | Boyle | May 2006 | B2 |
7058456 | Pierce | Jun 2006 | B2 |
7063707 | Bose | Jun 2006 | B2 |
7153320 | Euteneuer et al. | Dec 2006 | B2 |
7175655 | Malaei | Feb 2007 | B1 |
7179273 | Palmer et al. | Feb 2007 | B1 |
7220269 | Ansel | May 2007 | B1 |
7220271 | Clubb | May 2007 | B2 |
7226464 | Gamer et al. | Jun 2007 | B2 |
7229472 | DePalma et al. | Jun 2007 | B2 |
7232462 | Schaeffer | Jun 2007 | B2 |
7288112 | Denardo et al. | Oct 2007 | B2 |
7306618 | Demond | Dec 2007 | B2 |
7316692 | Huffmaster | Jan 2008 | B2 |
7323001 | Cubb | Jan 2008 | B2 |
7331976 | McGuckin, Jr. et al. | Feb 2008 | B2 |
7344550 | Carrison et al. | Mar 2008 | B2 |
7399308 | Borillo et al. | Jul 2008 | B2 |
7410491 | Hopkins | Aug 2008 | B2 |
7452496 | Brady et al. | Nov 2008 | B2 |
7491215 | Vale et al. | Feb 2009 | B2 |
7491216 | Brady | Feb 2009 | B2 |
7510565 | Gilson et al. | Mar 2009 | B2 |
7534252 | Sepetka | May 2009 | B2 |
7556636 | Mazzocchi | Jul 2009 | B2 |
7582111 | Krolik et al. | Sep 2009 | B2 |
7594926 | Inder | Sep 2009 | B2 |
7604649 | McGuckin et al. | Oct 2009 | B2 |
7618434 | Santra et al. | Nov 2009 | B2 |
7662165 | Gilson et al. | Feb 2010 | B2 |
7670356 | Mazzocchi | Mar 2010 | B2 |
7691121 | Rosenbluth | Apr 2010 | B2 |
7691124 | Balgobin | Apr 2010 | B2 |
7708770 | Linder | May 2010 | B2 |
7736385 | Agnew | Jun 2010 | B2 |
7766934 | Pal | Aug 2010 | B2 |
7771452 | Pal | Aug 2010 | B2 |
7780694 | Palmer | Aug 2010 | B2 |
7780696 | Daniel et al. | Aug 2010 | B2 |
7819893 | Brady et al. | Oct 2010 | B2 |
7828815 | Mazzocchi | Nov 2010 | B2 |
7846176 | Mazzocchi | Nov 2010 | B2 |
7846175 | Bonnette et al. | Dec 2010 | B2 |
7850708 | Pal | Dec 2010 | B2 |
7887560 | Kusleika | Feb 2011 | B2 |
7901426 | Gilson et al. | Mar 2011 | B2 |
7914549 | Morsi | Mar 2011 | B2 |
7922732 | Mazzocchi | Apr 2011 | B2 |
7927349 | Brady et al. | Apr 2011 | B2 |
7927784 | Simpson | Apr 2011 | B2 |
7931659 | Bose et al. | Apr 2011 | B2 |
7998165 | Huffmaster | Aug 2011 | B2 |
8002822 | Glocker et al. | Aug 2011 | B2 |
8021379 | Thompson et al. | Sep 2011 | B2 |
8021380 | Thompson et al. | Sep 2011 | B2 |
8043326 | Hancock et al. | Oct 2011 | B2 |
8048151 | O'Brien et al. | Nov 2011 | B2 |
8052640 | Fiorella et al. | Nov 2011 | B2 |
8057497 | Raju et al. | Nov 2011 | B1 |
8066757 | Ferrera et al. | Nov 2011 | B2 |
8070791 | Ferrera et al. | Dec 2011 | B2 |
8088140 | Ferrera et al. | Jan 2012 | B2 |
8100935 | Rosenbluth et al. | Jan 2012 | B2 |
8109941 | Richardson | Feb 2012 | B2 |
8118829 | Carrison et al. | Feb 2012 | B2 |
8123769 | Osborne | Feb 2012 | B2 |
8137377 | Palmer | Mar 2012 | B2 |
8142422 | Makower et al. | Mar 2012 | B2 |
8142442 | Palmer et al. | Mar 2012 | B2 |
8182508 | Magnuson et al. | May 2012 | B2 |
8187298 | Pal | May 2012 | B2 |
8246641 | Osborne et al. | Aug 2012 | B2 |
8246672 | Osborne | Aug 2012 | B2 |
8252017 | Paul, Jr. et al. | Aug 2012 | B2 |
8252018 | Valaie | Aug 2012 | B2 |
8357178 | Grandfield et al. | Jan 2013 | B2 |
8357179 | Grandfield et al. | Jan 2013 | B2 |
8357893 | Xu et al. | Jan 2013 | B2 |
8361095 | Osborne | Jan 2013 | B2 |
8366663 | Fiorella et al. | Feb 2013 | B2 |
8372133 | Douk et al. | Feb 2013 | B2 |
8382742 | Hermann et al. | Feb 2013 | B2 |
8409215 | Sepetka et al. | Apr 2013 | B2 |
8419748 | Valaie | Apr 2013 | B2 |
8460312 | Bose et al. | Jun 2013 | B2 |
8460313 | Huffmaster | Jun 2013 | B2 |
8486104 | Samson et al. | Jul 2013 | B2 |
8529596 | Grandfield et al. | Sep 2013 | B2 |
8574262 | Ferrera et al. | Nov 2013 | B2 |
8579915 | French et al. | Nov 2013 | B2 |
8585643 | Vo et al. | Nov 2013 | B2 |
8585713 | Ferrera et al. | Nov 2013 | B2 |
8608761 | Osbourne et al. | Dec 2013 | B2 |
8679142 | Slee et al. | Mar 2014 | B2 |
8696622 | Fiorella et al. | Apr 2014 | B2 |
8702652 | Fiorella et al. | Apr 2014 | B2 |
8702724 | Olsen et al. | Apr 2014 | B2 |
8784434 | Rosenbluth et al. | Jul 2014 | B2 |
8784441 | Rosenbluth et al. | Jul 2014 | B2 |
8795305 | Grandfield et al. | Aug 2014 | B2 |
8795317 | Grandfield et al. | Aug 2014 | B2 |
8795345 | Grandfield et al. | Aug 2014 | B2 |
8814892 | Galdonik et al. | Aug 2014 | B2 |
8814925 | Hilaire et al. | Aug 2014 | B2 |
8900265 | Ulm, III | Dec 2014 | B1 |
8939991 | Krolick et al. | Jan 2015 | B2 |
8945143 | Ferrera et al. | Feb 2015 | B2 |
8945172 | Ferrera et al. | Feb 2015 | B2 |
8968330 | Rosenbluth et al. | Mar 2015 | B2 |
9039749 | Shrivastava et al. | May 2015 | B2 |
9072537 | Grandfield et al. | Jul 2015 | B2 |
9113936 | Palmer et al. | Aug 2015 | B2 |
9119656 | Bose et al. | Sep 2015 | B2 |
9138307 | Valaie | Sep 2015 | B2 |
9149609 | Ansel et al. | Oct 2015 | B2 |
9155552 | Ulm, III | Oct 2015 | B2 |
9161766 | Slee et al. | Oct 2015 | B2 |
9173668 | Ulm, III | Nov 2015 | B2 |
9186487 | Dubrul et al. | Nov 2015 | B2 |
9198687 | Fulkerson et al. | Dec 2015 | B2 |
9204887 | Cully et al. | Dec 2015 | B2 |
9221132 | Bowman | Dec 2015 | B2 |
9232992 | Heidner | Jan 2016 | B2 |
9532792 | Galdonik et al. | Jan 2017 | B2 |
9532873 | Kelley | Jan 2017 | B2 |
9533344 | Monetti et al. | Jan 2017 | B2 |
9539011 | Chen et al. | Jan 2017 | B2 |
9539022 | Bowman | Jan 2017 | B2 |
9539122 | Burke et al. | Jan 2017 | B2 |
9539382 | Nelson | Jan 2017 | B2 |
9549830 | Bruszewski et al. | Jan 2017 | B2 |
9554805 | Tompkins et al. | Jan 2017 | B2 |
9561125 | Bowman et al. | Feb 2017 | B2 |
9572982 | Bumes et al. | Feb 2017 | B2 |
9579484 | Barnell | Feb 2017 | B2 |
9585642 | Dinsmoor et al. | Mar 2017 | B2 |
9615832 | Bose et al. | Apr 2017 | B2 |
9615951 | Bennett et al. | Apr 2017 | B2 |
9622753 | Cox | Apr 2017 | B2 |
9636115 | Henry et al. | May 2017 | B2 |
9636439 | Chu et al. | May 2017 | B2 |
9642635 | Vale et al. | May 2017 | B2 |
9642675 | Werneth et al. | May 2017 | B2 |
9655633 | Leynov et al. | May 2017 | B2 |
9655645 | Staunton | May 2017 | B2 |
9655989 | Cruise et al. | May 2017 | B2 |
9662129 | Galdonik et al. | May 2017 | B2 |
9662238 | Dwork et al. | May 2017 | B2 |
9662425 | Lilja et al. | May 2017 | B2 |
9668898 | Wong | Jun 2017 | B2 |
9675477 | Thompson | Jun 2017 | B2 |
9675782 | Connolly | Jun 2017 | B2 |
9676022 | Ensign et al. | Jun 2017 | B2 |
9692557 | Murphy | Jun 2017 | B2 |
9693852 | Lam et al. | Jul 2017 | B2 |
9700262 | Janik et al. | Jul 2017 | B2 |
9700399 | Acosta-Acevedo | Jul 2017 | B2 |
9717421 | Griswold et al. | Aug 2017 | B2 |
9717500 | Tieu et al. | Aug 2017 | B2 |
9717502 | Teoh et al. | Aug 2017 | B2 |
9724103 | Cruise et al. | Aug 2017 | B2 |
9724526 | Strother et al. | Aug 2017 | B2 |
9750565 | Bloom et al. | Sep 2017 | B2 |
9757260 | Greenan | Sep 2017 | B2 |
9764111 | Gulachenski | Sep 2017 | B2 |
9770251 | Bowman et al. | Sep 2017 | B2 |
9770577 | Li et al. | Sep 2017 | B2 |
9775621 | Tompkins et al. | Oct 2017 | B2 |
9775706 | Peterson et al. | Oct 2017 | B2 |
9775732 | Khenansho | Oct 2017 | B2 |
9788800 | Mayoras, Jr. | Oct 2017 | B2 |
9795391 | Saatchi et al. | Oct 2017 | B2 |
9801980 | Karino et al. | Oct 2017 | B2 |
9808599 | Bowman et al. | Nov 2017 | B2 |
9833252 | Sepetka et al. | Dec 2017 | B2 |
9833604 | Lam et al. | Dec 2017 | B2 |
9833625 | Waldhauser et al. | Dec 2017 | B2 |
10028759 | Wallace et al. | Jul 2018 | B2 |
10149692 | Turjman et al. | Dec 2018 | B2 |
10265086 | Vale | Apr 2019 | B2 |
10716915 | Ogle et al. | Jul 2020 | B2 |
10610668 | Burkholz et al. | Aug 2020 | B2 |
10835271 | Ma | Nov 2020 | B2 |
11076879 | Yee et al. | Aug 2021 | B2 |
20010001315 | Bates | May 2001 | A1 |
20010011182 | Dubrul et al. | Aug 2001 | A1 |
20010016755 | Addis | Aug 2001 | A1 |
20010041899 | Foster | Nov 2001 | A1 |
20010044598 | Parodi | Nov 2001 | A1 |
20010044634 | Don Michael et al. | Nov 2001 | A1 |
20010051810 | Dubrul | Dec 2001 | A1 |
20020002383 | Sepetka et al. | Jan 2002 | A1 |
20020016609 | Wensel | Feb 2002 | A1 |
20020022859 | Hogendijk | Feb 2002 | A1 |
20020026211 | Khosravi | Feb 2002 | A1 |
20020049468 | Streeter | Apr 2002 | A1 |
20020052620 | Barvut | May 2002 | A1 |
20020068954 | Foster | Jun 2002 | A1 |
20020072764 | Sepetka | Jun 2002 | A1 |
20020082558 | Samson | Jun 2002 | A1 |
20020091407 | Zadno-Azizi et al. | Jul 2002 | A1 |
20020095171 | Belef | Jul 2002 | A1 |
20020123765 | Sepetka | Sep 2002 | A1 |
20020143362 | Macoviak et al. | Oct 2002 | A1 |
20020156455 | Barbut | Oct 2002 | A1 |
20020161393 | Demond | Oct 2002 | A1 |
20020165576 | Boyle et al. | Nov 2002 | A1 |
20020173819 | Leeflang et al. | Nov 2002 | A1 |
20020177800 | Bagaoisan et al. | Nov 2002 | A1 |
20020188276 | Evans | Dec 2002 | A1 |
20030004536 | Boylan et al. | Jan 2003 | A1 |
20030004538 | Secrest | Jan 2003 | A1 |
20030004542 | Wensel | Jan 2003 | A1 |
20030009146 | Muni | Jan 2003 | A1 |
20030009191 | Wensel | Jan 2003 | A1 |
20030023204 | Vo et al. | Jan 2003 | A1 |
20030040769 | Kelley et al. | Feb 2003 | A1 |
20030040772 | Hyodoh et al. | Feb 2003 | A1 |
20030050663 | Khachin | Mar 2003 | A1 |
20030105484 | Boyle et al. | Jun 2003 | A1 |
20030125798 | Matrin | Jul 2003 | A1 |
20030130682 | Broome et al. | Jul 2003 | A1 |
20030144687 | Brady et al. | Jul 2003 | A1 |
20030144689 | Brady et al. | Jul 2003 | A1 |
20030153940 | Nohilly et al. | Aug 2003 | A1 |
20030153943 | Michael et al. | Aug 2003 | A1 |
20030153944 | Phung | Aug 2003 | A1 |
20030163064 | Vrba | Aug 2003 | A1 |
20030163158 | Wlite | Aug 2003 | A1 |
20030171769 | Barbu | Sep 2003 | A1 |
20030176884 | Berrada et al. | Sep 2003 | A1 |
20030187495 | Cully et al. | Oct 2003 | A1 |
20030195537 | Dubrul | Oct 2003 | A1 |
20030195554 | Shen | Oct 2003 | A1 |
20030199917 | Knudson | Oct 2003 | A1 |
20030204202 | Palmer | Oct 2003 | A1 |
20030212430 | Bose | Nov 2003 | A1 |
20030216611 | Q. Vu | Nov 2003 | A1 |
20030236533 | Wilson | Dec 2003 | A1 |
20040010280 | Adams et al. | Jan 2004 | A1 |
20040010282 | Kusleika | Jan 2004 | A1 |
20040014002 | Lundgren | Jan 2004 | A1 |
20040068288 | Palmer et al. | Apr 2004 | A1 |
20040073243 | Sepetka | Apr 2004 | A1 |
20040079429 | Miller | Apr 2004 | A1 |
20040082962 | Demarais et al. | Apr 2004 | A1 |
20040093065 | Yachia et al. | May 2004 | A1 |
20040133231 | Maitland | Jul 2004 | A1 |
20040138692 | Phung | Jul 2004 | A1 |
20040153049 | Tewitt et al. | Aug 2004 | A1 |
20040153118 | Clubb | Aug 2004 | A1 |
20040193107 | Pierpont et al. | Sep 2004 | A1 |
20040199202 | Dubrul et al. | Oct 2004 | A1 |
20040260333 | Dubrul et al. | Dec 2004 | A1 |
20050015047 | Shah | Jan 2005 | A1 |
20050020974 | Noriega | Jan 2005 | A1 |
20050033348 | Sepetka | Feb 2005 | A1 |
20050038447 | Huffmaster | Feb 2005 | A1 |
20050038468 | Panetta et al. | Feb 2005 | A1 |
20050049619 | Sepetka | Mar 2005 | A1 |
20050049669 | Jones | Mar 2005 | A1 |
20050049670 | Jones et al. | Mar 2005 | A1 |
20050055033 | Eslie et al. | Mar 2005 | A1 |
20050055047 | Greenhalgh | Mar 2005 | A1 |
20050059993 | Ramzipoor et al. | Mar 2005 | A1 |
20050059995 | Sepetka | Mar 2005 | A1 |
20050085849 | Sepetka | Apr 2005 | A1 |
20050090857 | Kusleika et al. | Apr 2005 | A1 |
20050119524 | Sckine et al. | Jun 2005 | A1 |
20050119668 | Teague et al. | Jun 2005 | A1 |
20050125024 | Sepetka | Jun 2005 | A1 |
20050131449 | Salahieh et al. | Jun 2005 | A1 |
20050149111 | Kanazawa et al. | Jul 2005 | A1 |
20050171566 | Kanamaru | Aug 2005 | A1 |
20050187570 | Nguyen et al. | Aug 2005 | A1 |
20050267491 | Kellett et al. | Aug 2005 | A1 |
20050216030 | Sepetka | Sep 2005 | A1 |
20050216050 | Sepetka | Sep 2005 | A1 |
20050288686 | Sepetka | Sep 2005 | A1 |
20050228417 | Teitelbaum et al. | Oct 2005 | A1 |
20060009785 | Maitland et al. | Jan 2006 | A1 |
20060009799 | Kleshinski et al. | Jan 2006 | A1 |
20060010636 | Vacher | Jan 2006 | A1 |
20060030933 | DeLeggge et al. | Feb 2006 | A1 |
20060036271 | Schomer et al. | Feb 2006 | A1 |
20060058836 | Bose | Mar 2006 | A1 |
20060058837 | Bose | Mar 2006 | A1 |
20060058838 | Bose | Mar 2006 | A1 |
20060064151 | Guterman et al. | Mar 2006 | A1 |
20060149313 | Arguello et al. | Jul 2006 | A1 |
20060155305 | Freudenthal | Jul 2006 | A1 |
20060155322 | Sater et al. | Jul 2006 | A1 |
20060161187 | Levine et al. | Jul 2006 | A1 |
20060195137 | Sepetka | Aug 2006 | A1 |
20060224177 | Finitsis | Oct 2006 | A1 |
20060224179 | Kucharczyk | Oct 2006 | A1 |
20060229638 | Abrams et al. | Oct 2006 | A1 |
20060282111 | Morsi | Dec 2006 | A1 |
20060287701 | Pal | Dec 2006 | A1 |
20070088383 | Pal et al. | Apr 2007 | A1 |
20070142858 | Bates | Jun 2007 | A1 |
20070149996 | Coughlin | Jun 2007 | A1 |
20070156170 | Hancock | Jul 2007 | A1 |
20070165170 | Fukuda | Jul 2007 | A1 |
20070179513 | Deutsch | Aug 2007 | A1 |
20070191866 | Palmer et al. | Aug 2007 | A1 |
20070198028 | Miloslavski | Aug 2007 | A1 |
20070198051 | Clubb et al. | Aug 2007 | A1 |
20070198075 | Levy | Aug 2007 | A1 |
20070208367 | Fiorella | Sep 2007 | A1 |
20070208371 | French | Sep 2007 | A1 |
20070213765 | Adams | Sep 2007 | A1 |
20070225749 | Martin | Sep 2007 | A1 |
20070239182 | Glines et al. | Oct 2007 | A1 |
20070239254 | Chia et al. | Oct 2007 | A1 |
20070244505 | Gilson et al. | Oct 2007 | A1 |
20070270902 | Slazas et al. | Nov 2007 | A1 |
20070288038 | Bimbo | Dec 2007 | A1 |
20070293887 | Okushi et al. | Dec 2007 | A1 |
20080045881 | Teitelbaum et al. | Feb 2008 | A1 |
20080082107 | Miller et al. | Apr 2008 | A1 |
20080086190 | Ta | Apr 2008 | A1 |
20080091223 | Pokorney | Apr 2008 | A1 |
20080097398 | Mitelberg | Apr 2008 | A1 |
20080109031 | Sepetka | May 2008 | A1 |
20080109032 | Sepetka | May 2008 | A1 |
20080119886 | Greenhalgh et al. | May 2008 | A1 |
20080177296 | Sepetka | Jul 2008 | A1 |
20080183197 | Sepetka | Jul 2008 | A1 |
20080183198 | Sepetka | Jul 2008 | A1 |
20080183205 | Sepetka | Jul 2008 | A1 |
20080188876 | Sepetka | Aug 2008 | A1 |
20080188885 | Sepetka | Aug 2008 | A1 |
20080188928 | Salahieh | Aug 2008 | A1 |
20080200946 | Braun | Aug 2008 | A1 |
20080215077 | Sepetka | Sep 2008 | A1 |
20080221600 | Dieck et al. | Sep 2008 | A1 |
20080228209 | DeMello et al. | Sep 2008 | A1 |
20080234706 | Sepetka | Sep 2008 | A1 |
20080243170 | Jenson | Oct 2008 | A1 |
20080255596 | Jenson | Oct 2008 | A1 |
20080262528 | Martin | Oct 2008 | A1 |
20080262532 | Martin | Oct 2008 | A1 |
20080269774 | Garcia et al. | Oct 2008 | A1 |
20080275488 | Fleming | Nov 2008 | A1 |
20080275493 | Farmiga | Nov 2008 | A1 |
20080281350 | Sepetka | Nov 2008 | A1 |
20080312681 | Ansel | Dec 2008 | A1 |
20090024157 | Anukhin | Jan 2009 | A1 |
20090054918 | Henson | Feb 2009 | A1 |
20090069828 | Martin | Mar 2009 | A1 |
20090076539 | Valaie | Mar 2009 | A1 |
20090105722 | Fulkerson | Apr 2009 | A1 |
20090105737 | Fulkerson | Apr 2009 | A1 |
20090131908 | Mckay | May 2009 | A1 |
20090163846 | Aklog et al. | May 2009 | A1 |
20090177206 | Lozier et al. | Jul 2009 | A1 |
20090182336 | Brenzel et al. | Jul 2009 | A1 |
20090221967 | Thommen et al. | Sep 2009 | A1 |
20090270815 | Stamp et al. | Oct 2009 | A1 |
20090281610 | Parker | Nov 2009 | A1 |
20090292297 | Ferrere | Nov 2009 | A1 |
20090292307 | Razack | Nov 2009 | A1 |
20090299374 | Tilson et al. | Dec 2009 | A1 |
20090299393 | Martin | Dec 2009 | A1 |
20090306702 | Miloslavski | Dec 2009 | A1 |
20100004607 | Wilson et al. | Jan 2010 | A1 |
20100016957 | Jager et al. | Jan 2010 | A1 |
20100030186 | Stivland | Feb 2010 | A1 |
20100030256 | Dubrul et al. | Feb 2010 | A1 |
20100036312 | Krolik et al. | Feb 2010 | A1 |
20100087908 | Hilaire | Apr 2010 | A1 |
20100114017 | Lenker | May 2010 | A1 |
20100125326 | Kalstad | May 2010 | A1 |
20100125327 | Agnew | May 2010 | A1 |
20100191272 | Keating | Jul 2010 | A1 |
20100211094 | Sargent, Jr. | Aug 2010 | A1 |
20100249815 | Jantzen et al. | Sep 2010 | A1 |
20100268264 | Bonnett et al. | Oct 2010 | A1 |
20100268265 | Krolik | Oct 2010 | A1 |
20100292726 | Olsen et al. | Nov 2010 | A1 |
20100305566 | Rosenblatt et al. | Dec 2010 | A1 |
20100305604 | Pah | Dec 2010 | A1 |
20100318178 | Rapaport et al. | Dec 2010 | A1 |
20100324649 | Mattsson | Dec 2010 | A1 |
20100331949 | Habib | Dec 2010 | A1 |
20110009875 | Grandfield et al. | Jan 2011 | A1 |
20110009940 | Grandfield et al. | Jan 2011 | A1 |
20110009942 | Gregorich | Jan 2011 | A1 |
20110022149 | Cox et al. | Jan 2011 | A1 |
20110054514 | Arcand | Mar 2011 | A1 |
20110054516 | Keegan | Mar 2011 | A1 |
20110060359 | Hannes | Mar 2011 | A1 |
20110071432 | Carrillo, Jr. et al. | Mar 2011 | A1 |
20110077620 | deBeer | Mar 2011 | A1 |
20110098683 | Wiita et al. | Apr 2011 | A1 |
20110054504 | Wolf et al. | May 2011 | A1 |
20110125181 | Brady et al. | May 2011 | A1 |
20110130756 | Everson, Jr. et al. | Jun 2011 | A1 |
20110152920 | Eckhouse et al. | Jun 2011 | A1 |
20110160763 | Ferrera et al. | Jun 2011 | A1 |
20110166586 | Sepetka et al. | Jul 2011 | A1 |
20110196414 | Porter et al. | Aug 2011 | A1 |
20110202088 | Eckhouse et al. | Aug 2011 | A1 |
20110213290 | Chin et al. | Sep 2011 | A1 |
20110213297 | Aklog et al. | Sep 2011 | A1 |
20110213393 | Aklog et al. | Sep 2011 | A1 |
20110213403 | Aboytes | Sep 2011 | A1 |
20110218564 | Drasler et al. | Sep 2011 | A1 |
20110224707 | Miloslavaski et al. | Sep 2011 | A1 |
20110264132 | Strauss et al. | Oct 2011 | A1 |
20110276120 | Gilson et al. | Nov 2011 | A1 |
20110319917 | Ferrera et al. | Dec 2011 | A1 |
20120041449 | Eckhouse et al. | Feb 2012 | A1 |
20120041474 | Eckhouse et al. | Feb 2012 | A1 |
20120059356 | diPama et al. | Mar 2012 | A1 |
20120089216 | Rapaport et al. | Apr 2012 | A1 |
20120101510 | Lenker et al. | Apr 2012 | A1 |
20120116351 | Chomas et al. | May 2012 | A1 |
20120116440 | Leynov et al. | May 2012 | A1 |
20120143237 | Cam et al. | Jun 2012 | A1 |
20120143239 | Aklog et al. | Jun 2012 | A1 |
20120150147 | Leynov et al. | Jun 2012 | A1 |
20120165858 | Eckhouse et al. | Jun 2012 | A1 |
20120165859 | Eckhouse et al. | Jun 2012 | A1 |
20120215250 | Grandfield et al. | Aug 2012 | A1 |
20120277788 | Cattaneo | Nov 2012 | A1 |
20120283768 | Cox et al. | Nov 2012 | A1 |
20120296362 | Cam et al. | Nov 2012 | A1 |
20120316600 | Ferrera et al. | Dec 2012 | A1 |
20130006284 | Aggerholm et al. | Jan 2013 | A1 |
20130030461 | Marks et al. | Jan 2013 | A1 |
20130046330 | McIntosh et al. | Feb 2013 | A1 |
20130046333 | Jones et al. | Feb 2013 | A1 |
20130046334 | Jones et al. | Feb 2013 | A1 |
20130116774 | Strauss et al. | May 2013 | A1 |
20130131614 | Hassan et al. | May 2013 | A1 |
20130144326 | Brady et al. | Jun 2013 | A1 |
20130144328 | Weber et al. | Jun 2013 | A1 |
20130158592 | Porter | Jun 2013 | A1 |
20130184703 | Shireman et al. | Jul 2013 | A1 |
20130184739 | Brady et al. | Jul 2013 | A1 |
20130197567 | Brady et al. | Aug 2013 | A1 |
20130226146 | Tekulve | Aug 2013 | A1 |
20130268050 | Wilson et al. | Oct 2013 | A1 |
20130281788 | Garrison | Oct 2013 | A1 |
20130289697 | Baker et al. | Oct 2013 | A1 |
20130325055 | Eckhouse et al. | Dec 2013 | A1 |
20130325056 | Eckhouse et al. | Dec 2013 | A1 |
20130345739 | Brady et al. | Dec 2013 | A1 |
20140012281 | Wang et al. | Jan 2014 | A1 |
20140046359 | Bowman et al. | Feb 2014 | A1 |
20140052097 | Petersen et al. | Feb 2014 | A1 |
20140081243 | Zhou et al. | Mar 2014 | A1 |
20140121672 | Folk | May 2014 | A1 |
20140128905 | Molaei | May 2014 | A1 |
20140135812 | Divino et al. | May 2014 | A1 |
20140180377 | Bose et al. | Jun 2014 | A1 |
20140188127 | Dubrul et al. | Jul 2014 | A1 |
20140194919 | Losordo et al. | Jul 2014 | A1 |
20140200607 | Sepetka et al. | Jul 2014 | A1 |
20140200608 | Brady et al. | Jul 2014 | A1 |
20140236220 | Inoue | Aug 2014 | A1 |
20140257018 | Farnan | Sep 2014 | A1 |
20140257362 | Eldenschink | Sep 2014 | A1 |
20140276922 | McLain et al. | Sep 2014 | A1 |
20140277003 | Hendrick | Sep 2014 | A1 |
20140277053 | Wang et al. | Sep 2014 | A1 |
20140277079 | Vale et al. | Sep 2014 | A1 |
20140309657 | Ben-Ami | Oct 2014 | A1 |
20140309673 | Dacuycuy et al. | Oct 2014 | A1 |
20140330302 | Tekulve et al. | Nov 2014 | A1 |
20140343585 | Ferrera et al. | Nov 2014 | A1 |
20140364896 | Consigny | Dec 2014 | A1 |
20140371769 | Vale et al. | Dec 2014 | A1 |
20140371777 | Rudakov et al. | Dec 2014 | A1 |
20140371779 | Vale et al. | Dec 2014 | A1 |
20140371780 | Vale et al. | Dec 2014 | A1 |
20140379023 | Brady et al. | Dec 2014 | A1 |
20150018859 | Quick et al. | Jan 2015 | A1 |
20150018860 | Quick et al. | Jan 2015 | A1 |
20150080937 | Davidson | Mar 2015 | A1 |
20150081003 | Wainwright et al. | Mar 2015 | A1 |
20150112376 | Molaei et al. | Apr 2015 | A1 |
20150133990 | Davidson | May 2015 | A1 |
20150142043 | Furey | May 2015 | A1 |
20150164523 | Brady et al. | Jun 2015 | A1 |
20150173782 | Garrison et al. | Jun 2015 | A1 |
20150173783 | Tah et al. | Jun 2015 | A1 |
20150238314 | Börtlein et al. | Aug 2015 | A1 |
20150250497 | Marks et al. | Sep 2015 | A1 |
20150257775 | Gilvarry et al. | Sep 2015 | A1 |
20150258270 | Kunis | Sep 2015 | A1 |
20150290437 | Rudakov et al. | Oct 2015 | A1 |
20150297252 | Miloslavski et al. | Oct 2015 | A1 |
20150306311 | Pinchuk et al. | Oct 2015 | A1 |
20150313617 | Grandfield et al. | Nov 2015 | A1 |
20150320431 | Ulm, III | Nov 2015 | A1 |
20150351770 | Fulton, III | Dec 2015 | A1 |
20150352325 | Quick | Dec 2015 | A1 |
20150359547 | Vale et al. | Dec 2015 | A1 |
20150374391 | Quick et al. | Dec 2015 | A1 |
20150374393 | Brady et al. | Dec 2015 | A1 |
20150374479 | Vale | Dec 2015 | A1 |
20160015402 | Brady et al. | Jan 2016 | A1 |
20160022296 | Brady et al. | Jan 2016 | A1 |
20160066921 | Brady et al. | Mar 2016 | A1 |
20160074067 | Furnish et al. | Mar 2016 | A1 |
20160106448 | Brady et al. | Apr 2016 | A1 |
20160106449 | Brady et al. | Apr 2016 | A1 |
20160113663 | Brady et al. | Apr 2016 | A1 |
20160113664 | Brady et al. | Apr 2016 | A1 |
20160113665 | Brady et al. | Apr 2016 | A1 |
20160120558 | Brady et al. | May 2016 | A1 |
20160121080 | Cottone | May 2016 | A1 |
20160135829 | Holochwost et al. | May 2016 | A1 |
20160143653 | Vale et al. | May 2016 | A1 |
20160151079 | Aklog et al. | Jun 2016 | A1 |
20160192953 | Brady et al. | Jul 2016 | A1 |
20160192954 | Brady et al. | Jul 2016 | A1 |
20160192955 | Brady et al. | Jul 2016 | A1 |
20160192956 | Brady et al. | Jul 2016 | A1 |
20160228134 | Martin et al. | Aug 2016 | A1 |
20160256180 | Vale et al. | Sep 2016 | A1 |
20160262880 | Li et al. | Sep 2016 | A1 |
20160317168 | Brady et al. | Nov 2016 | A1 |
20160346002 | Avneri et al. | Dec 2016 | A1 |
20170007264 | Cruise et al. | Jan 2017 | A1 |
20170007265 | Guo et al. | Jan 2017 | A1 |
20170020670 | Murray et al. | Jan 2017 | A1 |
20170020700 | Bienvenu et al. | Jan 2017 | A1 |
20170027640 | Kunis et al. | Feb 2017 | A1 |
20170027692 | Bonhoeffer et al. | Feb 2017 | A1 |
20170027725 | Argentine | Feb 2017 | A1 |
20170035436 | Morita | Feb 2017 | A1 |
20170035567 | Duffy | Feb 2017 | A1 |
20170042548 | Lam | Feb 2017 | A1 |
20170049596 | Schabert | Feb 2017 | A1 |
20170065401 | Fearnot et al. | Mar 2017 | A1 |
20170071614 | Vale et al. | Mar 2017 | A1 |
20170071737 | Kelley | Mar 2017 | A1 |
20170072452 | Monetti et al. | Mar 2017 | A1 |
20170079671 | Morero et al. | Mar 2017 | A1 |
20170079680 | Bowman | Mar 2017 | A1 |
20170079766 | Wang et al. | Mar 2017 | A1 |
20170079767 | Leon-Yip | Mar 2017 | A1 |
20170079812 | Lam et al. | Mar 2017 | A1 |
20170079817 | Sepetka et al. | Mar 2017 | A1 |
20170079819 | Pung et al. | Mar 2017 | A1 |
20170079820 | Lam et al. | Mar 2017 | A1 |
20170086851 | Wallace et al. | Mar 2017 | A1 |
20170086862 | Vale et al. | Mar 2017 | A1 |
20170086863 | Brady et al. | Mar 2017 | A1 |
20170086864 | Greenhalgh et al. | Mar 2017 | A1 |
20170086996 | Peterson et al. | Mar 2017 | A1 |
20170239447 | Greenhalgh et al. | Mar 2017 | A1 |
20170095138 | Nakade et al. | Apr 2017 | A1 |
20170095259 | Tompkins et al. | Apr 2017 | A1 |
20170100126 | Bowman et al. | Apr 2017 | A1 |
20170100141 | Morero et al. | Apr 2017 | A1 |
20170100143 | Granfield | Apr 2017 | A1 |
20170100183 | Iaizzo et al. | Apr 2017 | A1 |
20170105743 | Vale | Apr 2017 | A1 |
20170112515 | Brady et al. | Apr 2017 | A1 |
20170113023 | Steingisser et al. | Apr 2017 | A1 |
20170147765 | Mehta | May 2017 | A1 |
20170151032 | Loisel | Jun 2017 | A1 |
20170165062 | Rothstein | Jun 2017 | A1 |
20170165065 | Rothstein et al. | Jun 2017 | A1 |
20170165454 | Tuohy et al. | Jun 2017 | A1 |
20170172554 | Bortlein et al. | Jun 2017 | A1 |
20170172581 | Bose et al. | Jun 2017 | A1 |
20170172766 | Vong et al. | Jun 2017 | A1 |
20170172772 | Khenansho | Jun 2017 | A1 |
20170189033 | Sepetka et al. | Jul 2017 | A1 |
20170189035 | Porter | Jul 2017 | A1 |
20170215902 | Leynov et al. | Aug 2017 | A1 |
20170216484 | Cruise et al. | Aug 2017 | A1 |
20170224350 | Shimizu et al. | Aug 2017 | A1 |
20170224355 | Bowman et al. | Aug 2017 | A1 |
20170224467 | Piccagli et al. | Aug 2017 | A1 |
20170224511 | Dwork et al. | Aug 2017 | A1 |
20170224953 | Tran et al. | Aug 2017 | A1 |
20170231749 | Perkins et al. | Aug 2017 | A1 |
20170238953 | Yang et al. | Aug 2017 | A1 |
20170252043 | Fuller et al. | Sep 2017 | A1 |
20170252064 | Staunton | Sep 2017 | A1 |
20170259042 | Nguyen et al. | Sep 2017 | A1 |
20170265983 | Lam et al. | Sep 2017 | A1 |
20170281192 | Tieu et al. | Oct 2017 | A1 |
20170281331 | Perkins et al. | Oct 2017 | A1 |
20170281344 | Costello | Oct 2017 | A1 |
20170281909 | Northrop et al. | Oct 2017 | A1 |
20170281912 | Melder et al. | Oct 2017 | A1 |
20170290593 | Sethna | Oct 2017 | A1 |
20170290654 | Sethna | Oct 2017 | A1 |
20170296324 | Argentine | Oct 2017 | A1 |
20170296325 | Marrocco et al. | Oct 2017 | A1 |
20170303939 | Greenhalgh et al. | Oct 2017 | A1 |
20170303942 | Greenhalgh et al. | Oct 2017 | A1 |
20170303947 | Greenhalgh et al. | Oct 2017 | A1 |
20170303948 | Wallace et al. | Oct 2017 | A1 |
20170304041 | Argentine | Oct 2017 | A1 |
20170304097 | Corwin et al. | Oct 2017 | A1 |
20170304595 | Nagasrinivasa et al. | Oct 2017 | A1 |
20170312109 | Le | Nov 2017 | A1 |
20170312484 | Shipley et al. | Nov 2017 | A1 |
20170316561 | Helm et al. | Nov 2017 | A1 |
20170319826 | Bowman et al. | Nov 2017 | A1 |
20170333228 | Orth et al. | Nov 2017 | A1 |
20170333236 | Greenan | Nov 2017 | A1 |
20170333678 | Bowman et al. | Nov 2017 | A1 |
20170340383 | Bloom et al. | Nov 2017 | A1 |
20170348014 | Wallace et al. | Dec 2017 | A1 |
20170348514 | Guyon et al. | Dec 2017 | A1 |
20180008407 | Maimon et al. | Jan 2018 | A1 |
20180042623 | Batiste | Feb 2018 | A1 |
20180193050 | Hawkins et al. | Jul 2018 | A1 |
20180193591 | Jaroch et al. | Jul 2018 | A1 |
20180235743 | Farago et al. | Aug 2018 | A1 |
20180256177 | Cooper et al. | Sep 2018 | A1 |
20180303610 | Anderson | Oct 2018 | A1 |
20190021755 | Johnson et al. | Jan 2019 | A1 |
20190021759 | Krolik et al. | Jan 2019 | A1 |
20190029820 | Zhou et al. | Jan 2019 | A1 |
20190029825 | Fitterer et al. | Jan 2019 | A1 |
20190046219 | Marchand et al. | Feb 2019 | A1 |
20190192175 | Chida et al. | Jun 2019 | A1 |
20190209206 | Patel et al. | Jul 2019 | A1 |
20190216476 | Barry et al. | Jul 2019 | A1 |
20190239907 | Brady et al. | Aug 2019 | A1 |
20190247627 | Korkuch et al. | Aug 2019 | A1 |
20190255290 | Snyder et al. | Aug 2019 | A1 |
20190269491 | Jalgaonkar et al. | Sep 2019 | A1 |
20190274810 | Phouasalit et al. | Sep 2019 | A1 |
20190298396 | Gamba et al. | Oct 2019 | A1 |
20190365411 | Avneri et al. | Dec 2019 | A1 |
20190366049 | Hannon et al. | Dec 2019 | A1 |
20200038628 | Chou et al. | Feb 2020 | A1 |
20200214859 | Sherburne | Jul 2020 | A1 |
20200281611 | Kelly et al. | Sep 2020 | A1 |
20200353208 | Merhi et al. | Nov 2020 | A1 |
20200383698 | Miao et al. | Dec 2020 | A1 |
20210085935 | Fahey et al. | Mar 2021 | A1 |
20210153883 | Casey et al. | May 2021 | A1 |
20210153884 | Casey et al. | May 2021 | A1 |
20210154433 | Casey et al. | May 2021 | A1 |
20210219821 | Appling et al. | Jul 2021 | A1 |
20220117614 | Salmon et al. | Apr 2022 | A1 |
20220125450 | Sirhan | Apr 2022 | A1 |
20220313426 | Gifford, III et al. | Oct 2022 | A1 |
20230054898 | Gurovich et al. | Mar 2023 | A1 |
Number | Date | Country |
---|---|---|
1658920 | Aug 2005 | CN |
1972728 | May 2007 | CN |
103071195 | May 2013 | CN |
104507380 | Apr 2015 | CN |
104905873 | Sep 2015 | CN |
105007973 | Oct 2015 | CN |
105307582 | Feb 2016 | CN |
105726163 | Jul 2016 | CN |
106232059 | Dec 2016 | CN |
113040865 | Jun 2021 | CN |
20 2009 001 951 | Apr 2010 | DE |
10 2009 056 450 | Jun 2011 | DE |
10 2010 010 849 | Sep 2011 | DE |
10 2010 014 778 | Oct 2011 | DE |
10 2010 024 085 | Dec 2011 | DE |
10 2011 014 586 | Sep 2012 | DE |
20 2020 107013 | Jan 2021 | DE |
2301450 | Mar 2011 | EP |
2628455 | Aug 2013 | EP |
3302312 | Apr 2018 | EP |
3335647 | Jun 2018 | EP |
3 420 978 | Jan 2019 | EP |
4049704 | Aug 2022 | EP |
2498349 | Jul 2013 | GB |
9-19438 | Jan 1997 | JP |
2006021407 | Mar 2006 | NO |
WO 9304722 | Mar 1993 | WO |
9424926 | Nov 1994 | WO |
9727808 | Aug 1997 | WO |
9738631 | Oct 1997 | WO |
9920335 | Apr 1999 | WO |
9956801 | Nov 1999 | WO |
9960933 | Dec 1999 | WO |
0121077 | Mar 2001 | WO |
0202162 | Jan 2002 | WO |
0211627 | Feb 2002 | WO |
0243616 | Jun 2002 | WO |
02070061 | Sep 2002 | WO |
02094111 | Nov 2002 | WO |
03002006 | Jan 2003 | WO |
03018085 | Mar 2003 | WO |
03030751 | Apr 2003 | WO |
03051448 | Jun 2003 | WO |
2004028571 | Apr 2004 | WO |
2004056275 | Jul 2004 | WO |
2005000130 | Jan 2005 | WO |
2005027779 | Mar 2005 | WO |
WO 2005027751 | Mar 2005 | WO |
2006031410 | Mar 2006 | WO |
2006107641 | Oct 2006 | WO |
2006135823 | Dec 2006 | WO |
2007054307 | May 2007 | WO |
2007068424 | Jun 2007 | WO |
2008034615 | Mar 2008 | WO |
2008051431 | May 2008 | WO |
2008131116 | Oct 2008 | WO |
WO 2009019664 | Feb 2009 | WO |
2009031338 | Mar 2009 | WO |
2009076482 | Jun 2009 | WO |
2009086482 | Jul 2009 | WO |
2009105710 | Aug 2009 | WO |
WO 2009103125 | Aug 2009 | WO |
2010010545 | Jan 2010 | WO |
2010046897 | Apr 2010 | WO |
2010075565 | Jul 2010 | WO |
2010102307 | Sep 2010 | WO |
2010146581 | Dec 2010 | WO |
2011013556 | Feb 2011 | WO |
2011066961 | Jun 2011 | WO |
2011082319 | Jul 2011 | WO |
2011095352 | Aug 2011 | WO |
2011106426 | Sep 2011 | WO |
2011110316 | Sep 2011 | WO |
2012052982 | Apr 2012 | WO |
2012064726 | May 2012 | WO |
2012081020 | Jun 2012 | WO |
2012110619 | Aug 2012 | WO |
2012120490 | Sep 2012 | WO |
2012156924 | Nov 2012 | WO |
2013016435 | Jan 2013 | WO |
2013072777 | May 2013 | WO |
2013105099 | Jul 2013 | WO |
2013109756 | Jul 2013 | WO |
2014081892 | May 2014 | WO |
2014139845 | Sep 2014 | WO |
2014169266 | Oct 2014 | WO |
2014178198 | Nov 2014 | WO |
WO 2014188300 | Nov 2014 | WO |
2015061365 | Apr 2015 | WO |
2015134625 | Sep 2015 | WO |
2015179324 | Nov 2015 | WO |
WO 2015179377 | Nov 2015 | WO |
2015189354 | Dec 2015 | WO |
2016010995 | Jan 2016 | WO |
WO 2017004234 | Jan 2017 | WO |
WO 2017097616 | Jun 2017 | WO |
2018193603 | Oct 2018 | WO |
WO 2018178979 | Oct 2018 | WO |
WO 2019064306 | Apr 2019 | WO |
WO 2019079296 | Apr 2019 | WO |
WO 2020139979 | Jul 2020 | WO |
WO 2021016213 | Jan 2021 | WO |
WO 2021167653 | Aug 2021 | WO |
WO 2022020366 | Jan 2022 | WO |
Entry |
---|
US 6,348,062 B1, 02/2002, Hopkins (withdrawn) |
Struffert, T., et al. “Intravenous flat detector CT angiography for non-invasive visualisation of intracranial flow diverter: technical feasibility” Eur Radiol 21:1797-1801 (2011). |
Extended European Search Report issued in corresponding EP Application No. 21 16 5800 dated Oct. 27, 2021. |
Number | Date | Country | |
---|---|---|---|
20210298773 A1 | Sep 2021 | US |